Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study
Keywords:
obese, bimekizumab, psoriasis, safety, biologicReferences
Megna M, Di Costanzo L, Argenziano, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19:855–861. DOI: 10.1080/14712598.2019.1622678. PMID: 31140882.
Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1196966. DOI: 10.3389/fmed.2023.1196966. PMID: 37469659.
Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23:371–381. DOI: 10.1080/14712598.2023.2194485. PMID: 36971507.
Mastorino L, Susca S, Megna M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35. DOI: 10.1111/dth.15378. PMID: 35156278.
Wang J, Yu Y, Liu L, et al. Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades. Autoimmun Rev. 2024 Jun;23(6):103577. DOI: 10.1016/j.autrev.2024.103577. PMID: 39009055.
Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. DOI: 10.3389/fmed.2023.1243843. PMID: 37614958.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Zeno Fratton, Vincenzo Maione, Stefano Bighetti, Luca Bettolini, Giuseppe Stinco, Enzo Errichetti

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.